Risk of neoplasms with semaglutide in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials

Yuanyuan Zhong, Xing Tan, Ling Zhang, Cangui Wu

Open source

DOI
10.3389/fphar.2026.1916932
Published
2026-09-03
Container
Frontiers in Pharmacology
Publisher
Frontiers Media SA
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fphar.2026.1916932,
  title = {Risk of neoplasms with semaglutide in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials},
  author = {Yuanyuan Zhong and Xing Tan and Ling Zhang and Cangui Wu},
  year = {2026},
  journal = {Frontiers in Pharmacology},
  doi = {10.3389/fphar.2026.1916932},
  url = {https://doi.org/10.3389/fphar.2026.1916932}
}

RIS

TY  - JOUR
TI  - Risk of neoplasms with semaglutide in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
AU  - Yuanyuan Zhong
AU  - Xing Tan
AU  - Ling Zhang
AU  - Cangui Wu
PY  - 2026
JO  - Frontiers in Pharmacology
DO  - 10.3389/fphar.2026.1916932
UR  - https://doi.org/10.3389/fphar.2026.1916932
ER  - 

APA

Zhong, Y., Tan, X., Zhang, L., & Wu, C. (2026). Risk of neoplasms with semaglutide in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2026.1916932

Source records